CXCL12 plays an important role in a number of diseases. In cancer it has a key role in sustaining the tumour microenvironment and is implicated in ovarian and breast cancers. One strategy is to develop new drugs that block the formation of CXCL12 prior to the activation of its receptor CXCR4.
CXCL12 is a key inflammatory chemokine responsible for the metastasis of primary tumours to secondary sites. This study characterises novel CXCL12 inhibitors.
MSc Cancer therapies student project.
|Short title||Targerting CXCL12 in Breast cancer|
|Effective start/end date||13/05/19 → 2/09/19|